◼ Archived
Business
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.
Abbvie
14 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
◼ Archived
Health
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Former Apogee executives join Paragon Labs to scale R&D following an acquisition, while Alaunos Therapeutics secures major financing.
◼ Archived
Business
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
◼ Archived
Business
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
◼ Archived
Business
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.
◼ Archived
Business
🔮 fades
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.
◼ Archived
Business
🔮 fades
Lilly, J&J and AbbVie Hit New Highs
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
◼ Archived
Business
🔮 fades
AbbVie’s biggest deal since 2019 could land soon
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.